NCT02646332

Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy

Comparing the Efficacy and Impact on Gastrointestinal Microbiota of Reverse Hybrid Therapy and Concomitant Therapy in Helicobacter Pylori Eradication

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 248 (actual)
• Sponsor: Kaohsiung Veterans General Hospital. · Academic / Other
• Sex: All
• Age: 20 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Reverse hybrid therapy achieves a higher eradication rate than concomitant therapy remains unanswered.

Detailed description

A 14-day hybrid therapy invented by our study group appears very promising in H. pylori eradication, achieving excellent eradication rates of 99% and 97% according to per-protocol and intention-to-treat analyses, respectively. Recently, the investigators demonstrated that the eradication rate of reverse hybrid therapy was higher than that of standard triple therapy. However, whether reverse hybrid therapy achieves a higher eradication rate than concomitant therapy remains unanswered.

Conditions

• Helicobacter Pylori Infection

Interventions

Type	Name	Description
DRUG	(dexlan+amox+clar+metr)+(dexlan+amox)	a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
DRUG	dexlan+clarith+amox+metro	dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days

Timeline

• Start date: 2015-12-01
• Primary completion: 2020-07-31
• Completion: 2020-08-31
• First posted: 2016-01-05
• Last updated: 2020-11-24
• Results posted: 2020-11-24

Locations

1 site across 1 country: Taiwan